Biogen Inc

BIIB

$300.20

+51.2% last 12 months

Jim Simons Holding value: $379 Million Steven Cohen Holding value: $209 Million Ken Griffin Holding value: $73.6 Million Ray Dalio Holding value: $44.3 Million Jeremy Grantham Holding value: $42.2 Million Ken Fisher Holding value: $40.1 Million Joel Greenblatt Holding value: $5.97 Million David Abrams Holding value: $0 Mario Gabelli Holding value: $0 Cathie Wood Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Carl Icahn Holding value: $0 Michael Burry Holding value: $0 Warren Buffett Holding value: $0

Market Cap

$43.8 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$188.54 - $319.74

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

13.98x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $43.8 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $45 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +51.2%
52-Week High Highest share price in the last 52 weeks. $319.74
52-Week Low Lowest share price in the last 52 weeks. $188.54
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.97
Outstanding Shares The number of shares the company has issued and are held by stockholders. 145 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 861 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 13.98
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 50.5
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $21.53
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.35
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 3.16
Enterprise Value to Revenue Enterprise value divided by revenue 4.45
Enterprise Value to EBIT Enterprise Value divided by EBIT 16.17
Total Debt to Enterprise Value Total debt divided by enterprise value 0.14
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.46

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $10.1 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $7.92 Billion
EBIT Earnings before tax and interest payments. $2.78 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $3.13 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 30.99%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +27.7%
Return on Equity Equity divided by market cap. 22.69%
Return on Assets Indicates a company's profitability in relation to its total assets. 12.73%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 12.90%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2022 Q4 2022 Q1 2023 Q2 2023

About Biogen Inc

CEO: Josephine Price

Employees: 7,300

Industry: Biological Product (except Diagnostic) Manufacturing

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Similar stocks

AMGEN Inc.
AMGEN Inc.
Gilead Sciences, Inc.
Gilead Sciences, Inc.
Abbvie Inc
Abbvie Inc
Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Acorda Therapeutics Inc
Acorda Therapeutics Inc
Sanofi - ADR
Sanofi - ADR
Bio-Rad Laboratories Inc. - Class A
Bio-Rad Laboratories Inc. - Class A
Illumina Inc
Illumina Inc
Qiagen NV
Qiagen NV

News

Biogen and Denali Realign Parkinson''s Disease Research Priorities Amidst R&D Restructure

Biogen and Denali Realign Parkinson''s Disease Research Priorities Amidst R&D Restructure

In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB ) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinso...

Benzinga Benzinga, about 16 hours ago
Medicare to cover Alzheimer’s drugs, if they get full FDA approval

Medicare to cover Alzheimer’s drugs, if they get full FDA approval

A sign for the Food and Drug Administration is displayed outside its offices in Silver Spring, Md., on Dec. 10, 2020. Medicare has said it will cover Alzheim...

Deseret Deseret, 4 days ago
Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research

Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research

WASHINGTON, May 22, 2023 (GLOBE NEWSWIRE) -- The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD...

Benzinga Benzinga, 15 days ago
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer''s Disease in Great Britain

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer''s Disease in Great Britain

TOKYO, May 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) f...

Finanz Nachrichten Finanz Nachrichten, 15 days ago
Never miss a trade
To improve your user experience we use cookies.